- Home
- GENK vs CMMB Comparison
GENK vs CMMB Comparison
Compare GENK & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GENK | CMMB |
|---|---|---|
| Founded | 2011 | 2004 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.3M | 13.8M |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | GENK | CMMB |
|---|---|---|
| Price | $2.15 | $1.71 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | $5.67 | ★ $26.50 |
| AVG Volume (30 Days) | 45.9K | ★ 105.9K |
| Earning Date | 11-07-2025 | 11-20-2025 |
| Dividend Yield | ★ 1.34% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $217,449,000.00 | N/A |
| Revenue This Year | $10.35 | N/A |
| Revenue Next Year | $14.51 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 9.36 | N/A |
| 52 Week Low | $2.20 | $1.60 |
| 52 Week High | $7.87 | $9.84 |
Technical Indicators
Market Signals| Indicator | GENK | CMMB |
|---|---|---|
| Relative Strength Index (RSI) | 34.58 | 27.89 |
| Support Level | $2.21 | $1.60 |
| Resistance Level | $2.50 | $1.83 |
| Average True Range (ATR) | 0.11 | 0.25 |
| MACD | 0.00 | -0.03 |
| Stochastic Oscillator | 5.76 | 12.29 |
Price Performance
Historical ComparisonAbout GENK GEN Restaurant Group Inc.
GEN Restaurant Group Inc operates an Asian casual dining restaurant chain, offering an extensive menu of traditional Korean and Korean-American food, including high-quality meats, poultry, seafood, and mixed vegetables. It operates 43 Gen Korean BBQ restaurants in the United States.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.